These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10968431)

  • 1. Elusiveness of ideal approach to Pseudomonas aeruginosa infection complicating cystic fibrosis.
    Marshall BC; Liou TG
    Lancet; 2000 Aug; 356(9230):613-4. PubMed ID: 10968431
    [No Abstract]   [Full Text] [Related]  

  • 2. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
    Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
    Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhaled aztreonam.
    O'Sullivan BP; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 May; 9(5):357-8. PubMed ID: 20431562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of early Pseudomonas infection in cystic fibrosis.
    Lee TW
    Chron Respir Dis; 2009; 6(2):99-107. PubMed ID: 19411571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
    Farinde A
    Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
    [No Abstract]   [Full Text] [Related]  

  • 12. Eradication of Pseudomonas aeruginosa in cystic fibrosis.
    Eber E; Thalhammer GH; Zach MS
    Eur Respir J; 2006 Feb; 27(2):438-9. PubMed ID: 16452606
    [No Abstract]   [Full Text] [Related]  

  • 13. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation.
    Mainz JG; Michl R; Pfister W; Beck JF
    Am J Respir Crit Care Med; 2011 Nov; 184(9):1089-90. PubMed ID: 22045752
    [No Abstract]   [Full Text] [Related]  

  • 14. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
    Kernen Y; Sauty A; Roulet M
    Rev Med Suisse; 2005 Mar; 1(9):637-8, 640. PubMed ID: 15813341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
    Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis.
    Lim SZP; Fitzgerald DA
    Paediatr Respir Rev; 2018 Jun; 27():33-36. PubMed ID: 29033215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How should chronic Pseudomonas aeruginosa bronchial infection be treated in the course of cystic fibrosis?].
    Hubert D; Desmazes-Dufeu N; Dusser D
    Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S129-35. PubMed ID: 12910145
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Of isolates and isolation: Pseudomonas aeruginosa in adults with cystic fibrosis.
    Geddes DM
    Lancet; 2001 Aug; 358(9281):522-3. PubMed ID: 11520516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.